Non-motor symptoms in early Parkinson's disease: A 2-year follow-up study on previously untreated patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 1, 2013, Pages 14-17

  Erro, Roberto ^a   Picillo, Marina ^a   Vitale, Carmine ^b,c   Amboni, Marianna ^b,c   Moccia, Marcello ^a   Longo, Katia ^b   Cozzolino, Autilia ^d   Giordano, Flavio ^d   De Rosa, Anna ^a   De Michele, Giuseppe ^a   Pellecchia, Maria Teresa ^d   Barone, Paolo ^d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IDC Hermitage Capodimonte   (Italy)

^c UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMANTADINE; CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; QUETIAPINE; SERTRALINE;

ADULT; ANXIETY DISORDER; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DELUSION; DEPRESSION; DIPLOPIA; DIZZINESS; DRIBBLING; DYSPHAGIA; FALLING; FECES INCONTINENCE; FEMALE; FOLLOW UP; FORGETFULNESS; HALLUCINATION; HUMAN; INSOMNIA; INTESTINAL DYSMOTILITY; LIBIDO DISORDER; LOSS OF INTEREST; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL CONCENTRATION; MONOTHERAPY; NOCTURIA; PAIN; PARKINSON DISEASE; PATIENT REFERRAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTLESS LEGS SYNDROME; SAD; SEXUAL DYSFUNCTION; SIDE EFFECT; SMELLING DISORDER; SWEATING; SWELLING; TASTE DISORDER; URINARY URGENCY; VIVID DREAM; VOMITING; WEIGHT CHANGE;

EID: 84871251285     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-303419     Document Type: Article

References (33)

1. Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1449 outpatients with Parkinson's disease. J Neurol 2010;257:1073-82.
2. Erro R, Santangelo G, Picillo M, et al. Link between non-motor symptoms and cognitive dysfunctions in de novo, drug naive PD patients. J Neurol. Published Online First: 7 February 2012. doi:10.1007/s00415-011-6407-0.
3. The National Institute for Clinical Excellence (NICE). Parkinson's disease Diagnosis And Management In Primary And Secondary Care. Clinical guideline 35. 2006. http://www.nice.org.uk/nicemedia/pdf/cg035quickrefguide.pdf
4. Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-42. (Pubitemid 30637303)
5. Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003; 18:1139-45. (Pubitemid 37336937)
6. Den Oudsten BL, Van Heck GL, De Vries J. Quality of life and related concept in Parkinson's disease: a systematic review. Mov Disord 2007;22:1528-37. (Pubitemid 47477911)
7. Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's Disease. Mov Disord 2011;26 (Suppl 3):S42-80.
8. Park A, Stacy M. Non-motor symptoms in Parkinson's disease. J Neurol 2009;256(Suppl 3):S293-8.
9. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74.
10. Kim HJ, Park SY, Cho YJ, et al. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 2009;287:200-4.
11. Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions, and papid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 2005;20:1439-48. (Pubitemid 43072652)
12. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf 2010;33:147-61.
13. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa responsive problems dominate at 15 years. Mov Disord 2005;20:190-9. (Pubitemid 40361122)
14. Pappatà S, Santangelo G, Aarsland D, et al. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 2011;77:1357-62.
15. Fahn S, Elton RL. UPDRS program members (1987) Unified Parkinson's disease rating scale. In: Fahn S, Mardsen CD, Goldstein M, et al, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park. NJ: Macmillan Healthcare information, 1987:153-63.
16. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. An international multicentre pilot study of the the first comprehensive self-completed non motor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21:916-23. (Pubitemid 44184590)
17. Hughes AJ, Daniel SE, Kilford L, et al. The accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
18. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-85.
19. Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009;8:1158-71.
20. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-80.
21. Picillo M, Rocco M, Barone P. Dopamine receptor agonists and depression in Parkinson's disease. Parkinsonism Relat Disord 2010;15(Suppl 4):S81-4.
22. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003;10 :399-406. (Pubitemid 41754760)
23. Halbig TD, Assuras S, Creighton J, et al. Differential role of dopamine in emotional attention and memory: evidence from Parkinson's disease. Mov Disord 2011;26:1677-83.
24. Bloxham CA, Dick DJ, Moore M. Reaction time and attention in Parkinson's disease. J Neurol Neurosurg Psychiatry 1987;50:1178-83. (Pubitemid 17137829)
25. Fera F, Nicoletti G, Cerasa A, et al. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease. Brain Res Bull 2007;74:75-83. (Pubitemid 47187915)
26. Kulisevsky J, Garcia-Sanchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000;15:613-26. (Pubitemid 30479613)
27. Okun M, Walter BL, McDonald WM, et al. Beneficial effects of testosterone replacement for the non motor symptoms of Parkinson's disease. Arch Neurol 2002;59:1750-3. (Pubitemid 35340485)
28. Barone P, Antonini A, Colosimo C, et al. The Priamo study: a Multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24:1641-9.
29. Schestatsky P, Kumru H, Valls-Sole J, et al. Neurophysiologic study of central pain in patients with Parkinson's disease. Neurology 2007;69:2162-9. (Pubitemid 350294696)
30. Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical positron emission tomography study. Mov Disord 2005;20:1557-63.
31. Nirenberg MJ, Waters C. Compulsive Eating and weight gain related to dopamine agonist use. Mov Disord 2006;21:524-9.
32. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease. A cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-95.
33. Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international Setting; study using Nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007; 22:1623-9. (Pubitemid 47477925)